260 related articles for article (PubMed ID: 29359581)
1. A review discussing fluciclovine (
Zanoni L; Bossert I; Matti A; Schiavina R; Pultrone C; Fanti S; Nanni C
Future Oncol; 2018 May; 14(11):1101-1115. PubMed ID: 29359581
[TBL] [Abstract][Full Text] [Related]
2. Recurrent prostate cancer detection with anti-3-[(18)F]FACBC PET/CT: comparison with CT.
Odewole OA; Tade FI; Nieh PT; Savir-Baruch B; Jani AB; Master VA; Rossi PJ; Halkar RK; Osunkoya AO; Akin-Akintayo O; Zhang C; Chen Z; Goodman MM; Schuster DM
Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1773-83. PubMed ID: 27091135
[TBL] [Abstract][Full Text] [Related]
3. Fluorine-18-Labeled Fluciclovine PET/CT in Primary and Biochemical Recurrent Prostate Cancer Management.
Marcus C; Butler P; Bagrodia A; Cole S; Subramaniam RM
AJR Am J Roentgenol; 2020 Aug; 215(2):267-276. PubMed ID: 32551903
[No Abstract] [Full Text] [Related]
4. Utility of
Wang Y; Chow DZ; Ebert E; Tajmir S; Scott JA; Palmer EL
AJR Am J Roentgenol; 2020 Oct; 215(4):997-1001. PubMed ID: 32569513
[No Abstract] [Full Text] [Related]
5. The Impact of Positron Emission Tomography with 18F-Fluciclovine on the Treatment of Biochemical Recurrence of Prostate Cancer: Results from the LOCATE Trial.
Andriole GL; Kostakoglu L; Chau A; Duan F; Mahmood U; Mankoff DA; Schuster DM; Siegel BA;
J Urol; 2019 Feb; 201(2):322-331. PubMed ID: 30179618
[TBL] [Abstract][Full Text] [Related]
6. The role of
Kim SJ; Lee SW
Clin Radiol; 2019 Nov; 74(11):886-892. PubMed ID: 31358294
[TBL] [Abstract][Full Text] [Related]
7. PSMA-targeted Radiotracers versus
Tan N; Oyoyo U; Bavadian N; Ferguson N; Mukkamala A; Calais J; Davenport MS
Radiology; 2020 Jul; 296(1):44-55. PubMed ID: 32396045
[TBL] [Abstract][Full Text] [Related]
8. Prostate cancer recurrence in patients with negative or equivocal conventional imaging: A role for
Kim EH; Siegel BA; Teoh EJ; Andriole GL;
Urol Oncol; 2021 Jun; 39(6):365.e9-365.e16. PubMed ID: 33160848
[TBL] [Abstract][Full Text] [Related]
9. Fluorine-18-Labeled Fluciclovine PET/CT in Clinical Practice: Factors Affecting the Rate of Detection of Recurrent Prostate Cancer.
Savir-Baruch B; Lovrec P; Solanki AA; Adams WH; Yonover PM; Gupta G; Schuster DM
AJR Am J Roentgenol; 2019 Oct; 213(4):851-858. PubMed ID: 31216198
[No Abstract] [Full Text] [Related]
10. Extraprostatic Uptake of
Robertson MS; Sakellis CG; Hyun H; Jacene HA
AJR Am J Roentgenol; 2020 Mar; 214(3):641-648. PubMed ID: 31939697
[No Abstract] [Full Text] [Related]
11. The use of PET/CT in prostate cancer.
Li R; Ravizzini GC; Gorin MA; Maurer T; Eiber M; Cooperberg MR; Alemozzaffar M; Tollefson MK; Delacroix SE; Chapin BF
Prostate Cancer Prostatic Dis; 2018 Apr; 21(1):4-21. PubMed ID: 29230009
[TBL] [Abstract][Full Text] [Related]
12. The Clinical Utility of
Nakamoto R; Harrison C; Song H; Guja KE; Hatami N; Nguyen J; Moradi F; Franc BL; Aparici CM; Davidzon G; Iagaru A
Mol Imaging Biol; 2021 Aug; 23(4):614-623. PubMed ID: 33469884
[TBL] [Abstract][Full Text] [Related]
13. Patterns of Recurrence, Detection Rates, and Impact of 18-F Fluciclovine PET/CT on the Management of Men With Recurrent Prostate Cancer.
Michael J; Khandani AH; Basak R; Tan HJ; Royce TJ; Wallen E; Whang Y; Rose TL; Milowsky M; Bjurlin MA
Urology; 2021 Sep; 155():192-198. PubMed ID: 33516829
[TBL] [Abstract][Full Text] [Related]
14. New Clinical Indications for (18)F/(11)C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature.
Evangelista L; Briganti A; Fanti S; Joniau S; Reske S; Schiavina R; Stief C; Thalmann GN; Picchio M
Eur Urol; 2016 Jul; 70(1):161-175. PubMed ID: 26850970
[TBL] [Abstract][Full Text] [Related]
15. Multisite Experience of the Safety, Detection Rate and Diagnostic Performance of Fluciclovine (
Bach-Gansmo T; Nanni C; Nieh PT; Zanoni L; Bogsrud TV; Sletten H; Korsan KA; Kieboom J; Tade FI; Odewole O; Chau A; Ward P; Goodman MM; Fanti S; Schuster DM; Willoch F
J Urol; 2017 Mar; 197(3 Pt 1):676-683. PubMed ID: 27746282
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Diagnostic Utility of Fluciclovine PET/CT Versus Pelvic Multiparametric MRI for Prostate Cancer in the Pelvis in the Setting of Rising PSA After Initial Treatment.
Chen B; Bathala TK; Xu G; Teyateeti A; Chapin BF; Tang C; Tu SM; Macapinlac HA; Lu Y
Clin Nucl Med; 2020 May; 45(5):349-355. PubMed ID: 31977495
[TBL] [Abstract][Full Text] [Related]
17. ACR-ACNM Practice Parameter for the Performance of Fluorine-18 Fluciclovine-PET/CT for Recurrent Prostate Cancer.
Savir-Baruch B; Banks KP; McConathy JE; Molchanova-Cook OP; Parent EE; Takalkar A; Tulchinsky M; Yu JQ; Subramaniam RM; Schuster DM
Clin Nucl Med; 2018 Dec; 43(12):909-917. PubMed ID: 30325827
[TBL] [Abstract][Full Text] [Related]
18. 18F-Fluciclovine PET/CT for the Detection of Prostate Cancer Relapse: A Comparison to 11C-Choline PET/CT.
Nanni C; Schiavina R; Brunocilla E; Boschi S; Borghesi M; Zanoni L; Pettinato C; Martorana G; Fanti S
Clin Nucl Med; 2015 Aug; 40(8):e386-91. PubMed ID: 26053708
[TBL] [Abstract][Full Text] [Related]
19. Best Practices for
Tade FI; Sajdak RA; Gabriel M; Wagner RH; Savir-Baruch B
J Nucl Med Technol; 2019 Dec; 47(4):282-287. PubMed ID: 31182661
[No Abstract] [Full Text] [Related]
20. Prospective evaluation of fluciclovine (
Akin-Akintayo O; Tade F; Mittal P; Moreno C; Nieh PT; Rossi P; Patil D; Halkar R; Fei B; Master V; Jani AB; Kitajima H; Osunkoya AO; Ormenisan-Gherasim C; Goodman MM; Schuster DM
Eur J Radiol; 2018 May; 102():1-8. PubMed ID: 29685521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
